Previous 10 | Next 10 |
These 4 Penny Stocks Are Rallying Premarket; Can It Continue Throughout The Day? Penny stock trading is often seen as a way of getting rich quick. While penny stocks can actually bring large amounts of profits relatively quickly, it’s not as simple as it sounds. Penny stocks have ...
Cash balance anticipated to extend into 2021 Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the following updates to its clinical programs. ADXS-HOT: Cance...
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies ev...
Median overall survival for ADXS-PSA in combination with KEYTRUDA ® increased to 33.6 months from previously reported 21.1 months Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherap...
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results for the fiscal third quarter ended July 31, 2019. Key corpor...
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its chief executive officer, Kenneth A. Berlin, issued an open letter to Advaxis’ stockholders. The following...
Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the closing of its previously announced underwritten public offering of (i) 10,650,000 sh...
Thinly traded nano cap Advaxis ( ADXS -27% ) is down on almost a 7x surge in volume in response to its public offering of 9.2M common shares, common warrants to purchase up to 6.9M shares and ~13.7M pre-funded warrants together with common warrants to purchase up to ~10.2M shares. More...
Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 9,200,000 shares of common stock to...
Capricor Therapeutics (NASDAQ: CAPR ) +95% on positive CAP-1002 data . More news on: Capricor Therapeutics, Inc., Galapagos NV, Neon Therapeutics, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...